Dendrite Reports Third Quarter Financial Results

Share Name	Share Symbol	Market	Type
Dendrite International (MM)	NASDAQ:DRTE	NASDAQ	Common Stock

Dendrite (NASDAQ:DRTE)
Historical Stock Chart

From Mar 2020 to Mar 2025

Dendrite International, Inc. (NASDAQ: DRTE) today reported its financial results for the quarter ended September 30, 2006. Revenues for the quarter were $103.0 million, compared to revenues of $114.4 million in the prior year period. Year over year revenue comparisons are negatively affected by approximately $14 million of revenue in the prior period from the Company�s largest customer primarily related to a significant one-time project. On a GAAP basis, the Company reported a loss of $0.14 per diluted share in the third quarter 2006. Adjusted earnings per diluted share were $0.09 in the third quarter 2006, excluding $0.21 per share in severance and asset impairment charges and $0.02 per share in compensation expense (related to stock options and shares issued under the Company�s employee stock purchase plan). The Company reported that adjusted results also include approximately $0.02 per share of additional expense related to the implementation of its previously announced Operational Effectiveness program and strategic initiatives. GAAP earnings were $0.24 per diluted share for the third quarter 2005. �Dendrite�s repositioning is well underway, and our Operational Effectiveness program remains on track to generate our targeted savings of $40 million against our 2006 budget, which we expect will substantially enhance our bottom line going forward. With our exciting product development pipeline, streamlined cost structure and strengthened management team, we believe we are well positioned to both identify and capitalize on revenue growth opportunities in the months ahead,� stated Chief Operating Officer Joe Ripp. Segment Results Sales solutions Sales solutions revenue of $66.8 million was down 19% compared to $82.6 million in the third quarter of 2005, due largely to the previously noted non-recurring project in the third quarter 2005. Operating income in this segment decreased to $7.6 million for the quarter compared to $23.0 million in the prior year period. Third quarter 2006 Sales solutions operating income included approximately $5.8 million of restructuring charges related to severance for the Company�s Operational Effectiveness initiatives. Marketing solutions Marketing solutions revenue of $28.8 million in the third quarter 2006 increased 14% versus $25.3 million in the third quarter 2005. All regions experienced growth versus the prior year. Marketing solutions reported an operating loss of approximately $2.9 million in the third quarter 2006 compared to an operating loss of approximately $1.4 million in the third quarter of 2005. This change was due to additional selling and marketing efforts in support of future growth in this segment, as well as third quarter 2006 restructuring costs of $1.9 million. Emerging solutions Emerging solutions revenue of $7.4 million increased 15% from revenue of $6.4 million in the prior year period. The Emerging solutions segment reported operating income in the third quarter of 2006 of approximately $0.1 million; this was essentially flat compared to the same period of the prior year. Third quarter 2006 restructuring charges were $0.1 million for this segment. Corporate segment Dendrite reported Corporate expenses of $13.1 million in the third quarter of 2006 compared to $4.2 million in the third quarter of 2005, primarily reflecting the substantial costs the Company is incurring as it implements its Operational Effectiveness initiative. Costs associated with stock options and restricted stock units contributed nearly $2.0 million of additional expense in the third quarter 2006. The third quarter 2006 Corporate segment expense also included approximately $4.9 million of restructuring charges primarily related to an asset impairment charge related to a facility that Dendrite expects to sell as part of the Company�s Operational Effectiveness initiative. A further $2 million increase in Corporate segment expense is attributable primarily to consulting and other miscellaneous costs relating principally to the Company�s Operational Effectiveness program and other strategic initiatives. Summary of Key Balance Sheet Items The Company generated $13.3 million of cash from operations in the third quarter 2006. Days sales outstanding (DSO) was 59 days, remaining below the Company�s target of 60-63 days The Company ended the third quarter 2006 with $84.1 million in cash and cash equivalents. Total capital expenditures were $2.9 million in the third quarter 2006. Business Highlights Solid business performance was seen elsewhere in all three segments. Sales Solutions segment: Signed a global agreement with Procter and Gamble in Q406 to: Upgrade its core sales force automation solution to Dendrite�s Mobile Intelligence Extend its existing support services and prescriber data management solutions Add regional tool to enable greater territory and compliance management Secured contract expansions with Daiichi Sankyo and UCB, together adding more than 450 new sales force effectiveness users Launched the new Dendrite MICRO� mobile phone based sales force effectiveness solution and signed the first new customer In Europe, the Company entered into a significant three-year sales rep support services agreement with a prominent pharmaceutical company to implement and manage support services for over 1000 sales representatives in France Added more than 1000 new sales force effectiveness users in Europe, including two new customers on its human centered design based Mobile Intelligence� platform In Latin America, the Company implemented and rolled out its sales force effectiveness solution for approximately 350 users of Valeant, Mexico In Australia, the Company signed an agreement with BMS to upgrade to the latest version of Dendrite�s sales force automation solution, including a service renewal for three years. In Asia, the Company signed an agreement for its jforceNET� sales force effectiveness solution with its first domestic Korean pharmaceutical customer, LG Life Sciences Marketing Solutions segment: In the US, the Company closed forty new agreements with several customers, including seven with a leading pharmaceutical company for persistence campaigns and campaign management programs with a total contract value of over $ 4.5M. Acquired OPUS Health(TM), a leading provider of direct-to-patient persistence technologies. The acquisition enables Dendrite to add its breadth of marketing services around OPUS Health technology to deliver complete patient persistence programs and analysis. In Europe, increased penetration of our DocScan(R), Physician Connect(SM) and Market Research solutions, growing 32% versus the third quarter 2005. In Japan, the Company delivered its first two Physician Connect and DocScan projects for the region, following the recent launch of those offerings in the second quarter 2006. Emerging Solutions Segment: The Company�s Buzzeo Compliance group achieved a profitable quarter with a revenue increase of 18% year-to-date. Since its acquisition, the Company has rapidly expanded its customer base to include not only pharmaceutical companies, but also pharmaceutical distributors and pharmacy chains. Other Matters The Company revised its 2006 revenue outlook to approximately $419 to $424 million, down from $427 to $437 million, primarily as a result of slower than planned US Marketing Solutions sales in the second half of the year. From time to time the Company has received expressions of interest in strategic opportunities. As a consequence, the Board of Directors has appointed JPMorgan to advise the Board on their full range of options. The Company stated that there could be no assurances of any action as a result of their review and that it does not intend to discuss or provide interim updates. To participate in Dendrite�s earnings call to be telecast on November 2, 2006 at 5 p.m. EST, or to obtain replay information, please visit the Investors� Highlights Section of our website at www.dendrite.com. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company�s clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. FORWARD LOOKING INFORMATION: This document contains forward-looking statements that may be identified by such forward-looking terminology as �expect,� �believe,� �anticipate,� �will,� �intend,� �plan,� �target,� �outlook,� �guidance,� and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers, including the risk associated with our largest customer�s plans to transition a significant portion of its U.S. sales force effectiveness services needs; fluctuations in quarterly revenues due to lengthy sales and implementation cycles; our ability to successfully implement our Operational Effectiveness program and to achieve the cost savings in the amounts and time periods expected or budgeted; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; any difference between estimated and actual stock option expense; and risks associated with reviewing strategic options and with any transaction occurring or being consummated at any subsequent time. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K under �Factors That May Affect Future Results� and its 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved. Any�outlook and other forward-looking information is as of the date of this release only. At any such time in the future as the Company may provide revenue,�earnings and other outlook information, prior related outlook should no�longer be considered current. Our outlook and other forward-looking information do not take into account or reflect any possible future acquisitions, dispositions or similar transactions which may occur. TABLE 1 DENDRITE INTERNATIONAL, INC. � CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP � (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) � � Three Months Ended September 30, � 2006� % � 2005� % Change � Revenues: � Services & Technology: Sales solutions $ 66,762� 64.8% $ 82,642� 72.3% -19% Marketing solutions 28,835� 28.0% 25,310� 22.1% 14% Emerging solutions � 7,376� 7.2% � 6,408� 5.6% 15% Total revenues 102,973� 100.0% 114,360� 100.0% -10% � Operating Costs & Expenses: Operating costs (including shipping) 56,172� 54.6% 61,252� 53.6% -8% Selling, general and administrative 39,816� (1) 38.7% 33,395� (2) 29.2% 19% Research and development 1,607� 1.6% 1,343� 1.2% 20% Restructuring and other charges 12,660� (3) 12.3% -� 0.0% NM� Amortization of acquired intangible assets � 1,074� 1.0% � 960� 0.8% 12% Total operating costs & expenses 111,329� 108.1% 96,950� 84.8% 15% � Operating (loss) income (8,356) -8.1% 17,410� 15.2% NM� � Interest income, net (644) -0.6% (150) -0.1% NM� Other expense, net � 31� 0.0% � 35� 0.0% NM� � (Loss) income before income tax (benefit) expense (7,743) -7.5% 17,525� 15.3% 144% � Income tax (benefit) expense � (1,698) -1.6% � 6,747� 5.9% 125% � Net (loss) income $ (6,045) -5.9% $ 10,778� 9.4% 156% � Net (loss) income per share: Basic $ (0.14) $ 0.25� NM� Diluted $ (0.14) $ 0.24� NM� � Shares used in computing net (loss) income per share: Basic � 43,713� � 42,944� Diluted � 43,713� � 44,331� (1) Includes $937 out of $975 total stock-based compensation expense from the adoption of SFAS 123(R) and $887 out of $905 total restricted stock expense, respectively. (2) Includes $69 of restricted stock expense. (3) $8,206 of severance expense and $4,454 of an asset impairment charge. � NM - Not meaningful. TABLE 2 DENDRITE INTERNATIONAL, INC. � CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP � (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) � � Nine Months Ended September 30, � 2006� % � 2005� % Change � Revenues: � Services & Technology: Sales solutions $ 202,316� 64.7% $ 230,641� 70.1% -12% Marketing solutions 90,414� 28.9% 79,091� 24.0% 14% Emerging solutions � 19,753� 6.3% � 19,141� 5.8% 3% Total revenues 312,483� 100.0% 328,873� 100.0% -5% � Operating Costs & Expenses: Operating costs (including shipping) 175,321� 56.1% 173,732� 52.8% 1% Selling, general and administrative 121,707� (1) 38.9% 103,258� (2) 31.4% 18% Research and development 4,835� 1.5% 4,615� 1.4% 5% Restructuring and other charges 15,238� (3) 4.9% 9,372� (4) 2.8% 63% Amortization of acquired intangible assets � 3,131� 1.0% � 3,340� 1.0% -6% Total operating costs & expenses 320,232� 102.5% 294,317� 89.5% 9% � Operating (loss) income (7,749) -2.5% 34,556� 10.5% -122% � Interest income, net (1,602) -0.5% (315) -0.1% NM� Other expense, net � 77� 0.0% � 32� 0.0% NM� � (Loss) income before income tax expense (6,224) -2.0% 34,839� 10.6% 118% � (Loss) income before income tax (benefit) expense � (174) -0.1% � 13,413� 4.1% 101% � Net (loss) income $ (6,050) -1.9% $ 21,426� 6.5% 128% � Net (loss) income per share: Basic $ (0.14) $ 0.50� NM� Diluted $ (0.14) $ 0.49� NM� � Shares used in computing net (loss) income per share: Basic � 43,638� � 42,670� Diluted � 43,638� � 43,903� � � (1) Includes $3,392 out of $3,591 total stock-based compensation expense from the adoption of SFAS 123(R) and $2,213 out of $2,244 total restricted stock expense, respectively. (2) Includes $103 of restricted stock expense. (3) $10,248 of severance expense, $4,454 of an asset impairment charge and $536 of other expense. (4) $7,649 of facility related charges and $1,723 of severance expense. � NM-Not Meaningful TABLE 3 DENDRITE INTERNATIONAL, INC. � SUPPLEMENTAL FINANCIAL INFORMATION (SEE NOTES) � (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) � � � � � � � � � � � � � � � � � Three Months Ended September 30, Nine Months Ended September 30, 2006� 2005� % Change� 2006� 2005� % Change� � Total revenue - GAAP $ 102,973� $ 114,360� -10% $ 312,483� $ 328,873� -5% � Impact of foreign exchange rates (1) 748� -� 3,459� -� � Total revenue - Adjusted $ 103,721� $ 114,360� -9% $ 315,942� $ 328,873� -4% � � � � � � � � � � � � � � � � � � � � � � � � � � � � � Three Months Ended September 30, Nine Months Ended September 30, � 2006� � 2005� � 2006� � 2005� Operating (loss) income - GAAP $ (8,356) $ 17,410� $ (7,749) $ 34,556� � Stock option expense (2) 1,023� -� 3,750� -� Surplus facility charges (3) -� -� -� 7,649� Severance charges 8,206� (5) -� 10,248� (5) 1,723� (4) Asset impairment 4,454� (7) -� 4,454� (7) -� Other restructuring charges � -� � -� � 536� (6) � -� � Operating income - Adjusted $ 5,327� $ 17,410� $ 11,239� $ 43,928� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � Three Months Ended September 30, Nine Months Ended September 30, � 2006� � 2005� � 2006� � 2005� Net income per share: Diluted - GAAP $ (0.14) $ 0.24� $ (0.14) $ 0.49� � Stock option expense (2) 0.02� (8) -� 0.06� (8) -� Surplus facility charges (3) -� -� -� 0.10� (9) Severance charges 0.15� (10) -� 0.17� (10) 0.03� (11) Asset impairment 0.06� (12) -� 0.06� (12) -� Other restructuring charges � -� � -� � 0.01� (13) � -� � Diluted - Adjusted $ 0.09� $ 0.24� $ 0.17� $ 0.62� � � � � � � � � � � � � � � � � � � Note: 2006 EPS does not foot down due to the mathematical rounding ofthe individual calculations. � (1) The impact of exchange rates are calculated by taking 2006 local currency revenue and applying the 2005 exchange rates for comparison purposes. � (2) Prior to January 1, 2006, the Company accounted for stock-based compensation under Accounting Principles Board, Opinion No. 25, �Accounting for Stock Issued to Employees� (�APB 25�). In accordance with APB 25, the Company historically used the intrinsic value method to account for stock-based compensation expense. Under APB 25, stock options and shares issued under the Company�s employee stock purchase plan were not an expense for accounting purposes and, as a result, no compensation expense is included in the 2005 reporting period related to these items. As of January 1, 2006, the Company accounts for stock-based compensation expense, including expense related to stock options and shares issued under the employee stock purchase program, under the fair value method of Statement of Financial Accounting No. 123(R), �Shared-Based Payment� (�FAS 123(R)�). As the Company adopted the modified prospective method, results for prior periods have not been restated under the fair value method for GAAP purposes. � (3) The surplus facility charges relates to vacating a New Jersey facility and for additional facilities vacated in previous periods due to changes in market conditions, as well as the write-off of leasehold improvements associated with the exited facility. � (4) The 2005 severance charges relates to the elimination of certain senior and mid-level management positions. � (5) The 2006 severance charges relates to the elimination of certain positions relating to our Operational Effectiveness initiative ("OE"). � (6) The 2006 other restructuring charges primarily relates to the refocusing of our Japanese business. � (7) The 2006 asset impairment charge relates to a facility held for sale that was reduced to its estimated fair market value less costs to sell. � (8) The tax effect using the marginal tax rate is $352 and $1,248 for the three and nine months ended September 30, 2006, respectively. � (9) The tax effect using the marginal tax rate is $3,075 for the nine months ended September 30, 2005. � (10) The tax effect using the marginal tax rate is $1,658 and $2,352 for the three and nine months ended September 30, 2006, respectively. � (11) The tax effect using the marginal tax rate is $487 for the nine months ended September 30, 2005. � (12) The tax effect using the marginal tax rate is $1,782 for the three and nine months ended September 30, 2006. � (13) The tax effect using the marginal tax rate is $226 for the nine months ended September 30, 2006. TABLE 4 DENDRITE INTERNATIONAL, INC. � SEGMENT REVENUE, OPERATING INCOME (LOSS) AND RESTRUCTURING AND OTHER CHARGES � (IN THOUSANDS) (UNAUDITED) � For the Three Months Ended September 30, 2006 Sales Solutions Marketing Solutions� Emerging Solutions Corporate Total Revenue $ 66,762� $ 28,835� $ 7,376� $ -� $ 102,973� Operating income (loss) $ 7,570� $ (2,919) $ 137� $ (13,144) $ (8,356) Restructuring charges $ 5,758� $ 1,930� $ 63� $ 4,909� $ 12,660� � � For the Three Months Ended September 30, 2005 Sales Solutions Marketing Solutions� Emerging Solutions Corporate Total Revenue $ 82,642� $ 25,310� $ 6,408� $ -� $ 114,360� Operating income (loss) $ 23,019� $ (1,440) $ 69� $ (4,238) $ 17,410� Restructuring charges $ -� $ -� $ -� $ -� $ -� � � For the Nine Months Ended September 30, 2006 Sales Solutions Marketing Solutions Emerging Solutions Corporate Total Revenue $ 202,316� $ 90,414� $ 19,753� $ -� $ 312,483� Operating income (loss) $ 33,751� $ (8,253) $ (379) $ (32,868) $ (7,749) Restructuring charges $ 6,517� $ 2,884� $ 67� $ 5,770� $ 15,238� � � For the Nine Months Ended September 30, 2005 Sales solutions Marketing solutions� Emerging solutions Corporate Total Revenue $ 230,641� $ 79,091� $ 19,141� $ -� $ 328,873� Operating income (loss) $ 56,433� $ (3,566) $ 970� $ (19,281) $ 34,556� Restructuring charges $ -� $ -� $ -� $ 9,372� $ 9,372� TABLE 5 DENDRITE INTERNATIONAL, INC. � CONSOLIDATED BALANCE SHEETS � (IN THOUSANDS, EXCEPT SHARE DATA) (UNAUDITED) � September 30, 2006 December 31, 2005 Assets � Current Assets: Cash and cash equivalents $ 84,147� $ 66,145� Accounts receivable, net 67,106� 80,167� Prepaid expenses and other current assets 7,945� 8,544� Asset held for sale 8,545� -� Deferred income taxes � 13,035� � 8,848� Total current assets � 180,778� � 163,704� � Property and equipment, net 38,578� 52,592� Other assets 9,355� 8,856� Goodwill 92,332� 90,440� Intangible assets, net 27,038� 25,083� Capitalized software development costs, net 10,380� 10,341� Deferred income taxes � 12,011� � 11,991� $ 370,472� $ 363,007� Liabilities and Stockholders' Equity � Current Liabilities: Accounts payable $ 8,138� $ 7,677� Income taxes payable 8,272� 9,518� Capital lease obligations 1,408� 1,383� Accrued compensation and benefits 18,887� 17,950� Accrued professional and consulting fees 6,164� 5,690� Accrued restructuring and other charges 8,138� 1,490� Other accrued expenses 20,376� 17,468� Purchase accounting restructuring accrual 960� 1,601� Deferred revenues � 15,430� � 18,680� Total current liabilities � 87,773� � 81,457� � Capital lease obligations 389� 1,648� Purchase accounting restructuring accrual 2,269� 3,009� Accrued restructuring and other charges 3,387� 4,143� Deferred rent 5,425� 5,740� Other non-current liabilities 5,617� 5,595� � Stockholders' Equity: Preferred stock, no par value, 15,000,000 shares authorized, none issued -� -� Common stock, no par value, 150,000,000 shares authorized, 46,583,869 and 46,353,252 shares issued; 43,722,566 and 43,491,949 shares outstanding at September 30, 2006 and December 31, 2005, respectively 153,728� 149,947� Retained earnings 142,899� 148,948� Deferred compensation -� (4,419) Accumulated other comprehensive income (loss) 722� (1,324) Less treasury stock, at cost � (31,737) � (31,737) � Total stockholders' equity 265,612� 261,415� � $ 370,472� $ 363,007� TABLE 6 DENDRITE INTERNATIONAL, INC. � CONSOLIDATED STATEMENTS OF CASH FLOWS � (IN THOUSANDS) (UNAUDITED) � Nine Months Ended September 30, � 2006� � 2005� Operating activities: Net (loss) income $ (6,050) $ 21,426� Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 19,090� 18,026� Asset impairment 4,454� 1,030� Stock-based compensation 5,941� 103� Deferred income taxes (3,869) (2,277) Excess tax benefits from stock-based awards (229) -� Changes in assets and liabilities, net of effects from acquisitions: Decrease (increase) in accounts receivable 14,725� (1,825) Decrease in prepaid expenses and other current assets 860� 56� Increase in other assets (368) (1,277) Increase in accounts payable and accrued expenses 567� 1,599� Increase in accrued restructuring and other charges 5,829� 6,618� Decrease in purchase accounting restructuring accrual (1,118) (2,180) Decrease in income taxes payable (1,004) (1,621) (Decrease) increase in deferred revenue (3,579) 221� Decrease in other non-current liabilities � (2) � (70) � Net cash provided by operating activities � 35,247� � 39,829� � Investing activities: Acquisitions, net of cash acquired (5,706) (21,439) Purchases of property and equipment (9,863) (22,633) Additions to capitalized software development costs � (3,668) � (3,845) � Net cash used in investing activities � (19,237) � (47,917) � Financing activities: Payments on capital lease obligations (1,234) (1,241) Excess tax benefits from stock-based awards 229� -� Issuance of common stock � 2,030� � 10,938� � Net cash provided by financing activities � 1,025� � 9,697� � Effect of foreign exchange rate changes on cash 967� (1,011) � Net increase in cash and cash equivalents 18,002� 598� Cash and cash equivalents, beginning of year � 66,145� � 64,020� � Cash and cash equivalents, end of period $ 84,147� $ 64,618� Dendrite International, Inc. (NASDAQ: DRTE) today reported its financial results for the quarter ended September 30, 2006. Revenues for the quarter were $103.0 million, compared to revenues of $114.4 million in the prior year period. Year over year revenue comparisons are negatively affected by approximately $14 million of revenue in the prior period from the Company's largest customer primarily related to a significant one-time project. On a GAAP basis, the Company reported a loss of $0.14 per diluted share in the third quarter 2006. Adjusted earnings per diluted share were $0.09 in the third quarter 2006, excluding $0.21 per share in severance and asset impairment charges and $0.02 per share in compensation expense (related to stock options and shares issued under the Company's employee stock purchase plan). The Company reported that adjusted results also include approximately $0.02 per share of additional expense related to the implementation of its previously announced Operational Effectiveness program and strategic initiatives. GAAP earnings were $0.24 per diluted share for the third quarter 2005. "Dendrite's repositioning is well underway, and our Operational Effectiveness program remains on track to generate our targeted savings of $40 million against our 2006 budget, which we expect will substantially enhance our bottom line going forward. With our exciting product development pipeline, streamlined cost structure and strengthened management team, we believe we are well positioned to both identify and capitalize on revenue growth opportunities in the months ahead," stated Chief Operating Officer Joe Ripp. Segment Results Sales solutions Sales solutions revenue of $66.8 million was down 19% compared to $82.6 million in the third quarter of 2005, due largely to the previously noted non-recurring project in the third quarter 2005. Operating income in this segment decreased to $7.6 million for the quarter compared to $23.0 million in the prior year period. Third quarter 2006 Sales solutions operating income included approximately $5.8 million of restructuring charges related to severance for the Company's Operational Effectiveness initiatives. Marketing solutions Marketing solutions revenue of $28.8 million in the third quarter 2006 increased 14% versus $25.3 million in the third quarter 2005. All regions experienced growth versus the prior year. Marketing solutions reported an operating loss of approximately $2.9 million in the third quarter 2006 compared to an operating loss of approximately $1.4 million in the third quarter of 2005. This change was due to additional selling and marketing efforts in support of future growth in this segment, as well as third quarter 2006 restructuring costs of $1.9 million. Emerging solutions Emerging solutions revenue of $7.4 million increased 15% from revenue of $6.4 million in the prior year period. The Emerging solutions segment reported operating income in the third quarter of 2006 of approximately $0.1 million; this was essentially flat compared to the same period of the prior year. Third quarter 2006 restructuring charges were $0.1 million for this segment. Corporate segment Dendrite reported Corporate expenses of $13.1 million in the third quarter of 2006 compared to $4.2 million in the third quarter of 2005, primarily reflecting the substantial costs the Company is incurring as it implements its Operational Effectiveness initiative. Costs associated with stock options and restricted stock units contributed nearly $2.0 million of additional expense in the third quarter 2006. The third quarter 2006 Corporate segment expense also included approximately $4.9 million of restructuring charges primarily related to an asset impairment charge related to a facility that Dendrite expects to sell as part of the Company's Operational Effectiveness initiative. A further $2 million increase in Corporate segment expense is attributable primarily to consulting and other miscellaneous costs relating principally to the Company's Operational Effectiveness program and other strategic initiatives. Summary of Key Balance Sheet Items -- The Company generated $13.3 million of cash from operations in the third quarter 2006. -- Days sales outstanding (DSO) was 59 days, remaining below the Company's target of 60-63 days -- The Company ended the third quarter 2006 with $84.1 million in cash and cash equivalents. -- Total capital expenditures were $2.9 million in the third quarter 2006. Business Highlights Solid business performance was seen elsewhere in all three segments. Sales Solutions segment: -- Signed a global agreement with Procter and Gamble in Q406 to: -- Upgrade its core sales force automation solution to Dendrite's Mobile Intelligence -- Extend its existing support services and prescriber data management solutions -- Add regional tool to enable greater territory and compliance management -- Secured contract expansions with Daiichi Sankyo and UCB, together adding more than 450 new sales force effectiveness users -- Launched the new Dendrite MICRO(TM) mobile phone based sales force effectiveness solution and signed the first new customer -- In Europe, the Company entered into a significant three-year sales rep support services agreement with a prominent pharmaceutical company to implement and manage support services for over 1000 sales representatives in France -- Added more than 1000 new sales force effectiveness users in Europe, including two new customers on its human centered design based Mobile Intelligence(TM) platform -- In Latin America, the Company implemented and rolled out its sales force effectiveness solution for approximately 350 users of Valeant, Mexico -- In Australia, the Company signed an agreement with BMS to upgrade to the latest version of Dendrite's sales force automation solution, including a service renewal for three years. -- In Asia, the Company signed an agreement for its jforceNET(TM) sales force effectiveness solution with its first domestic Korean pharmaceutical customer, LG Life Sciences Marketing Solutions segment: -- In the US, the Company closed forty new agreements with several customers, including seven with a leading pharmaceutical company for persistence campaigns and campaign management programs with a total contract value of over $ 4.5M. -- Acquired OPUS Health(TM), a leading provider of direct-to-patient persistence technologies. The acquisition enables Dendrite to add its breadth of marketing services around OPUS Health technology to deliver complete patient persistence programs and analysis. -- In Europe, increased penetration of our DocScan(R), Physician Connect(SM) and Market Research solutions, growing 32% versus the third quarter 2005. In Japan, the Company delivered its first two Physician Connect and DocScan projects for the region, following the recent launch of those offerings in the second quarter 2006. Emerging Solutions Segment: -- The Company's Buzzeo Compliance group achieved a profitable quarter with a revenue increase of 18% year-to-date. Since its acquisition, the Company has rapidly expanded its customer base to include not only pharmaceutical companies, but also pharmaceutical distributors and pharmacy chains. Other Matters The Company revised its 2006 revenue outlook to approximately $419 to $424 million, down from $427 to $437 million, primarily as a result of slower than planned US Marketing Solutions sales in the second half of the year. From time to time the Company has received expressions of interest in strategic opportunities. As a consequence, the Board of Directors has appointed JPMorgan to advise the Board on their full range of options. The Company stated that there could be no assurances of any action as a result of their review and that it does not intend to discuss or provide interim updates. To participate in Dendrite's earnings call to be telecast on November 2, 2006 at 5 p.m. EST, or to obtain replay information, please visit the Investors' Highlights Section of our website at www.dendrite.com. -0- *T About Dendrite *T Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. FORWARD LOOKING INFORMATION: This document contains forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers, including the risk associated with our largest customer's plans to transition a significant portion of its U.S. sales force effectiveness services needs; fluctuations in quarterly revenues due to lengthy sales and implementation cycles; our ability to successfully implement our Operational Effectiveness program and to achieve the cost savings in the amounts and time periods expected or budgeted; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; any difference between estimated and actual stock option expense; and risks associated with reviewing strategic options and with any transaction occurring or being consummated at any subsequent time. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K under "Factors That May Affect Future Results" and its 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved. Any outlook and other forward-looking information is as of the date of this release only. At any such time in the future as the Company may provide revenue, earnings and other outlook information, prior related outlook should no longer be considered current. Our outlook and other forward-looking information do not take into account or reflect any possible future acquisitions, dispositions or similar transactions which may occur. -0- *T TABLE 1 DENDRITE INTERNATIONAL, INC. CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) Three Months Ended September 30, --------------------------------------------- 2006 % 2005 % Change --------- ------ --------- ------ ------ Revenues: Services & Technology: Sales solutions $ 66,762 64.8% $ 82,642 72.3% -19% Marketing solutions 28,835 28.0% 25,310 22.1% 14% Emerging solutions 7,376 7.2% 6,408 5.6% 15% --------- --------- Total revenues 102,973 100.0% 114,360 100.0% -10% Operating Costs & Expenses: Operating costs (including shipping) 56,172 54.6% 61,252 53.6% -8% Selling, general and administrative 39,816 (1) 38.7% 33,395 (2) 29.2% 19% Research and development 1,607 1.6% 1,343 1.2% 20% Restructuring and other charges 12,660 (3) 12.3% - 0.0% NM Amortization of acquired intangible assets 1,074 1.0% 960 0.8% 12% --------- --------- Total operating costs & expenses 111,329 108.1% 96,950 84.8% 15% Operating (loss) income (8,356) -8.1% 17,410 15.2% NM Interest income, net (644) -0.6% (150) -0.1% NM Other expense, net 31 0.0% 35 0.0% NM --------- --------- (Loss) income before income tax (benefit) expense (7,743) -7.5% 17,525 15.3% 144% Income tax (benefit) expense (1,698) -1.6% 6,747 5.9% 125% --------- --------- Net (loss) income $ (6,045) -5.9% $ 10,778 9.4% 156% ========= ========= Net (loss) income per share: Basic $ (0.14) $ 0.25 NM ========= ========= Diluted $ (0.14) $ 0.24 NM ========= ========= Shares used in computing net (loss) income per share: Basic 43,713 42,944 --------- --------- Diluted 43,713 44,331 --------- --------- (1) Includes $937 out of $975 total stock-based compensation expense from the adoption of SFAS 123(R) and $887 out of $905 total restricted stock expense, respectively. (2) Includes $69 of restricted stock expense. (3) $8,206 of severance expense and $4,454 of an asset impairment charge. NM - Not meaningful. *T -0- *T TABLE 2 DENDRITE INTERNATIONAL, INC. CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) Nine Months Ended September 30, ------------------------------------------- 2006 % 2005 % Change --------- ------ --------- ------------ Revenues: Services & Technology: Sales solutions $202,316 64.7% $230,641 70.1% -12% Marketing solutions 90,414 28.9% 79,091 24.0% 14% Emerging solutions 19,753 6.3% 19,141 5.8% 3% --------- --------- Total revenues 312,483 100.0% 328,873 100.0% -5% Operating Costs & Expenses: Operating costs (including shipping) 175,321 56.1% 173,732 52.8% 1% Selling, general and administrative 121,707 (1) 38.9% 103,258 (2) 31.4% 18% Research and development 4,835 1.5% 4,615 1.4% 5% Restructuring and other charges 15,238 (3) 4.9% 9,372 (4) 2.8% 63% Amortization of acquired intangible assets 3,131 1.0% 3,340 1.0% -6% --------- --------- Total operating costs & expenses 320,232 102.5% 294,317 89.5% 9% Operating (loss) income (7,749) -2.5% 34,556 10.5% -122% Interest income, net (1,602) -0.5% (315) -0.1% NM Other expense, net 77 0.0% 32 0.0% NM --------- --------- (Loss) income before income tax expense (6,224) -2.0% 34,839 10.6% 118% (Loss) income before income tax (benefit) expense (174) -0.1% 13,413 4.1% 101% --------- --------- Net (loss) income $ (6,050) -1.9% $ 21,426 6.5% 128% ========= ========= Net (loss) income per share: Basic $ (0.14) $ 0.50 NM ========= ========= Diluted $ (0.14) $ 0.49 NM ========= ========= Shares used in computing net (loss) income per share: Basic 43,638 42,670 --------- --------- Diluted 43,638 43,903 --------- --------- (1) Includes $3,392 out of $3,591 total stock-based compensation expense from the adoption of SFAS 123(R) and $2,213 out of $2,244 total restricted stock expense, respectively. (2) Includes $103 of restricted stock expense. (3) $10,248 of severance expense, $4,454 of an asset impairment charge and $536 of other expense. (4) $7,649 of facility related charges and $1,723 of severance expense. NM-Not Meaningful *T -0- *T TABLE 3 DENDRITE INTERNATIONAL, INC. SUPPLEMENTAL FINANCIAL INFORMATION (SEE NOTES) (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) ---------------------------------------------------------------------- Three Months Ended Nine Months Ended September 30, September 30, ----------------------------- ----------------------------- 2006 2005 % Change 2006 2005 % Change --------- --------- --------- --------- --------- --------- Total revenue - GAAP $102,973 $114,360 -10% $312,483 $328,873 -5% Impact of foreign exchange rates (1) 748 - 3,459 - --------- --------- --------- --------- Total revenue - Adjusted $103,721 $114,360 -9% $315,942 $328,873 -4% ========= ========= ========= ========= ---------------------------------------------------------------------- *T -0- *T ---------------------------------------------------------------------- Three Months Ended Nine Months Ended September 30, September 30, ---------------------- ---------------------- 2006 2005 2006 2005 -------- -------- -------- -------- Operating (loss) income - GAAP $(8,356) $17,410 $(7,749) $34,556 Stock option expense (2) 1,023 - 3,750 - Surplus facility charges (3) - - - 7,649 Severance charges 8,206 (5) - 10,248 (5) 1,723 (4) Asset impairment 4,454 (7) - 4,454 (7) - Other restructuring charges - - 536 (6) - -------- -------- -------- -------- Operating income - Adjusted $ 5,327 $17,410 $11,239 $43,928 ======== ======== ======== ======== ---------------------------------------------------------------------- *T -0- *T ---------------------------------------------------------------------- Three Months Ended Nine Months Ended September 30, September 30, -------------------- --------------------- 2006 2005 2006 2005 ------- ------ ------- ------ Net income per share: Diluted - GAAP $(0.14) $0.24 $(0.14) $0.49 Stock option expense (2) 0.02 (8) - 0.06 (8) - Surplus facility charges (3) - - - 0.10 (9) Severance charges 0.15 (10) - 0.17 (10) 0.03 (11) Asset impairment 0.06 (12) - 0.06 (12) - Other restructuring charges - - 0.01 (13) - ------- ------ ------- ------ Diluted - Adjusted $ 0.09 $0.24 $ 0.17 $0.62 ======= ====== ======= ====== ---------------------------------------------------------------------- Note: 2006 EPS does not foot down due to the mathematical rounding of the individual calculations. (1) The impact of exchange rates are calculated by taking 2006 local currency revenue and applying the 2005 exchange rates for comparison purposes. (2) Prior to January 1, 2006, the Company accounted for stock-based compensation under Accounting Principles Board, Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25"). In accordance with APB 25, the Company historically used the intrinsic value method to account for stock-based compensation expense. Under APB 25, stock options and shares issued under the Company's employee stock purchase plan were not an expense for accounting purposes and, as a result, no compensation expense is included in the 2005 reporting period related to these items. As of January 1, 2006, the Company accounts for stock-based compensation expense, including expense related to stock options and shares issued under the employee stock purchase program, under the fair value method of Statement of Financial Accounting No. 123(R), "Shared-Based Payment" ("FAS 123(R)"). As the Company adopted the modified prospective method, results for prior periods have not been restated under the fair value method for GAAP purposes. (3) The surplus facility charges relates to vacating a New Jersey facility and for additional facilities vacated in previous periods due to changes in market conditions, as well as the write-off of leasehold improvements associated with the exited facility. (4) The 2005 severance charges relates to the elimination of certain senior and mid-level management positions. (5) The 2006 severance charges relates to the elimination of certain positions relating to our Operational Effectiveness initiative ("OE"). (6) The 2006 other restructuring charges primarily relates to the refocusing of our Japanese business. (7) The 2006 asset impairment charge relates to a facility held for sale that was reduced to its estimated fair market value less costs to sell. (8) The tax effect using the marginal tax rate is $352 and $1,248 for the three and nine months ended September 30, 2006, respectively. (9) The tax effect using the marginal tax rate is $3,075 for the nine months ended September 30, 2005. (10) The tax effect using the marginal tax rate is $1,658 and $2,352 for the three and nine months ended September 30, 2006, respectively. (11) The tax effect using the marginal tax rate is $487 for the nine months ended September 30, 2005. (12) The tax effect using the marginal tax rate is $1,782 for the three and nine months ended September 30, 2006. (13) The tax effect using the marginal tax rate is $226 for the nine months ended September 30, 2006. *T -0- *T TABLE 4 DENDRITE INTERNATIONAL, INC. SEGMENT REVENUE, OPERATING INCOME (LOSS) AND RESTRUCTURING AND OTHER CHARGES (IN THOUSANDS) (UNAUDITED) For the Three Months Ended September 30, 2006 ----------------------------------------------------- Sales Marketing Emerging Solutions Solutions Solutions Corporate Total ---------- ---------- ---------- --------- --------- Revenue $ 66,762 $28,835 $ 7,376 $ - $102,973 Operating income (loss) $ 7,570 $(2,919) $ 137 $(13,144) $ (8,356) Restructuring charges $ 5,758 $ 1,930 $ 63 $ 4,909 $ 12,660 For the Three Months Ended September 30, 2005 ----------------------------------------------------- Sales Marketing Emerging Solutions Solutions Solutions Corporate Total ---------- ---------- ---------- --------- --------- Revenue $ 82,642 $25,310 $ 6,408 $ - $114,360 Operating income (loss) $ 23,019 $(1,440) $ 69 $ (4,238) $ 17,410 Restructuring charges $ - $ - $ - $ - $ - For the Nine Months Ended September 30, 2006 ----------------------------------------------------- Sales Marketing Emerging Solutions Solutions Solutions Corporate Total ---------- ---------- ---------- --------- --------- Revenue $202,316 $90,414 $19,753 $ - $312,483 Operating income (loss) $ 33,751 $(8,253) $ (379) $(32,868) $ (7,749) Restructuring charges $ 6,517 $ 2,884 $ 67 $ 5,770 $ 15,238 For the Nine Months Ended September 30, 2005 ----------------------------------------------------- Sales Marketing Emerging solutions solutions solutions Corporate Total ---------- ---------- ---------- --------- --------- Revenue $230,641 $79,091 $19,141 $ - $328,873 Operating income (loss) $ 56,433 $(3,566) $ 970 $(19,281) $ 34,556 Restructuring charges $ - $ - $ - $ 9,372 $ 9,372 *T -0- *T TABLE 5 DENDRITE INTERNATIONAL, INC. CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE DATA) (UNAUDITED) September 30, December 31, 2006 2005 ------------- ------------ Assets Current Assets: Cash and cash equivalents $ 84,147 $ 66,145 Accounts receivable, net 67,106 80,167 Prepaid expenses and other current assets 7,945 8,544 Asset held for sale 8,545 - Deferred income taxes 13,035 8,848 ------------- ------------ Total current assets 180,778 163,704 ------------- ------------ Property and equipment, net 38,578 52,592 Other assets 9,355 8,856 Goodwill 92,332 90,440 Intangible assets, net 27,038 25,083 Capitalized software development costs, net 10,380 10,341 Deferred income taxes 12,011 11,991 ------------- ------------ $ 370,472 $363,007 ============= ============ Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ 8,138 $ 7,677 Income taxes payable 8,272 9,518 Capital lease obligations 1,408 1,383 Accrued compensation and benefits 18,887 17,950 Accrued professional and consulting fees 6,164 5,690 Accrued restructuring and other charges 8,138 1,490 Other accrued expenses 20,376 17,468 Purchase accounting restructuring accrual 960 1,601 Deferred revenues 15,430 18,680 ------------- ------------ Total current liabilities 87,773 81,457 ------------- ------------ Capital lease obligations 389 1,648 Purchase accounting restructuring accrual 2,269 3,009 Accrued restructuring and other charges 3,387 4,143 Deferred rent 5,425 5,740 Other non-current liabilities 5,617 5,595 Stockholders' Equity: Preferred stock, no par value, 15,000,000 shares authorized, none issued - - Common stock, no par value, 150,000,000 shares authorized, 46,583,869 and 46,353,252 shares issued; 43,722,566 and 43,491,949 shares outstanding at September 30, 2006 and December 31, 2005, respectively 153,728 149,947 Retained earnings 142,899 148,948 Deferred compensation - (4,419) Accumulated other comprehensive income (loss) 722 (1,324) Less treasury stock, at cost (31,737) (31,737) ------------- ------------ Total stockholders' equity 265,612 261,415 $ 370,472 $363,007 ============= ============ *T -0- *T TABLE 6 DENDRITE INTERNATIONAL, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS) (UNAUDITED) Nine Months Ended September 30, ------------------- 2006 2005 --------- --------- Operating activities: Net (loss) income $ (6,050) $ 21,426 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 19,090 18,026 Asset impairment 4,454 1,030 Stock-based compensation 5,941 103 Deferred income taxes (3,869) (2,277) Excess tax benefits from stock-based awards (229) - Changes in assets and liabilities, net of effects from acquisitions: Decrease (increase) in accounts receivable 14,725 (1,825) Decrease in prepaid expenses and other current assets 860 56 Increase in other assets (368) (1,277) Increase in accounts payable and accrued expenses 567 1,599 Increase in accrued restructuring and other charges 5,829 6,618 Decrease in purchase accounting restructuring accrual (1,118) (2,180) Decrease in income taxes payable (1,004) (1,621) (Decrease) increase in deferred revenue (3,579) 221 Decrease in other non-current liabilities (2) (70) --------- --------- Net cash provided by operating activities 35,247 39,829 --------- --------- Investing activities: Acquisitions, net of cash acquired (5,706) (21,439) Purchases of property and equipment (9,863) (22,633) Additions to capitalized software development costs (3,668) (3,845) --------- --------- Net cash used in investing activities (19,237) (47,917) --------- --------- Financing activities: Payments on capital lease obligations (1,234) (1,241) Excess tax benefits from stock-based awards 229 - Issuance of common stock 2,030 10,938 --------- --------- Net cash provided by financing activities 1,025 9,697 --------- --------- Effect of foreign exchange rate changes on cash 967 (1,011) Net increase in cash and cash equivalents 18,002 598 Cash and cash equivalents, beginning of year 66,145 64,020 --------- --------- Cash and cash equivalents, end of period $ 84,147 $ 64,618 ========= ========= *T

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

DRTE Dendrite International (MM)